This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by MacDonald, T. T. Articles by Gordon, J. N. Search for Related Content PubMed PubMed Citation Articles by MacDonald, T. T. Articles by Gordon, J. N. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Crohn's Disease Genetics Home Reference Social Bookmarking                   What's this?

Immunopathogenesis of Crohn's Disease

From the Division of Infection, Inflammation and Repair, University of Southampton School of Medicine, Southampton, United Kingdom

Correspondence: Thomas T MacDonald, Professor of Immunology and Director of the Division of Infection, Allergy, Inflammation and Repair, Mailpoint 813, Level E, South Block, University of Southampton School of Medicine, Southampton SO16 6YD, UK. Electronic mail may be sent to t.t.macdonald{at}soton.ac.uk.

This review highlights the huge advances made in the understanding of Crohn's disease in the last 15 years. The pathogenic immune response in the gut wall is a highly polarised T helper cell type 1 response, probably directed against antigens of the commensal flora. There is marked over-expression of pro-inflammatory cytokines such as tumor necrosis factor (TNF)- and increased production of matrix degrading enzymes by fibroblasts and macrophages, which are probably responsible for ulceration and fistula formation. Crohn's disease runs in families and the susceptibility genes identified so far are associated with innate recognition of microbial products (Nod2) or epithelial barrier function (OCTN cation transporter genes and DLG5). Endogenous healing pathways mediated by transforming growth factor (TGF)-β1 are inhibited because mucosal inflammatory cells express Smad7, the endogenous intracellular inhibitor of TGF-β signalling. This makes it unlikely that enteral feeds containing TFG-β are therapeutic by means of direct anti-inflammatory effects, however TGF-β may still be involved because it is a well known epithelial motogen and may promote mucosal healing, in synergy with changes in mucosal bacterial populations as a result of the change in the diet.

Discussion

Journal of Parenteral and Enteral Nutrition, Vol. 29, No. 4 suppl, S118-S125 (2005)
DOI: 10.1177/01486071050290S4S118


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Fichtner-Feigl, I. J. Fuss, C. A. Young, T. Watanabe, E. K. Geissler, H.-J. Schlitt, A. Kitani, and W. Strober Induction of IL-13 Triggers TGF-beta1-Dependent Tissue Fibrosis in Chronic 2,4,6-Trinitrobenzene Sulfonic Acid Colitis J. Immunol., May 1, 2007; 178(9): 5859 - 5870. [Abstract] [Full Text] [PDF]